VTAK vs DBVT vs ALKS vs ATRC vs JNJ

For growth investors, AtriCure, Inc.

(ATRC) is the stronger pick with 14. 9% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 5x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

5x versus Johnson & Johnson at 38. 2x. On forward P/E, Johnson & Johnson is actually cheaper at 19. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +61.

7%, compared to -100. 0% for Catheter Precision, Inc. (VTAK). Over 10 years, the gap is even starker: JNJ returned +131. 3% versus VTAK's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

04β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 2707% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 51% for Johnson & Johnson — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AtriCure, Inc.

(ATRC) is pulling ahead at 14. 9% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, VTAK leads at 167. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -39. 6% for Catheter Precision, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus -26. 8% for VTAK. At the gross margin level — before operating expenses — VTAK leads at 90. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Johnson & Johnson (JNJ) trades at 19.

1x forward P/E versus 428. 7x for AtriCure, Inc. — 409. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 134. 8% to $46. 33.

In this comparison, JNJ (2.

2% yield) pays a dividend. VTAK, DBVT, ALKS, ATRC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), 2. 2% yield, +131. 3% 10Y return). Both have compounded well over 10 years (JNJ: +131. 3%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

JNJ pays a dividend while VTAK, DBVT, ALKS, ATRC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.